A5046387225- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Retinoids in leukemia and cellular processes
- Multiple Myeloma Research and Treatments
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Hematopoietic Stem Cell Transplantation
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Breast Cancer Treatment Studies
- Cancer Immunotherapy and Biomarkers
- Lymphoma Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Advanced biosensing and bioanalysis techniques
- Statistical Methods in Clinical Trials
- Colorectal Cancer Surgical Treatments
- Immune cells in cancer
- Neutropenia and Cancer Infections
- Cancer Treatment and Pharmacology
- Pelvic floor disorders treatments
- Health Systems, Economic Evaluations, Quality of Life
University of Oxford
2004-2024
Cardiff University
2012-2023
Nuffield Health
2019-2021
National Cancer Research Institute
2018-2019
University College London
2005-2018
King's College London
2004-2018
Queen Mary University of London
2018
Newcastle upon Tyne Hospitals NHS Foundation Trust
2018
North Bristol NHS Trust
2013-2018
University of Liverpool
2009-2018
Despite the molecular heterogeneity of standard-risk acute myeloid leukemia (AML), treatment decisions are based on a limited number genetic markers and morphology-based assessment remission. Sensitive detection leukemia-specific marker (e.g., mutation in gene encoding nucleophosmin [NPM1]) could improve prognostication by identifying submicroscopic disease during
Clinical trials have shown the benefits of cholinesterase inhibitors for treatment mild-to-moderate Alzheimer's disease. It is not known whether continue after progression to moderate-to-severe
Purpose Antibody-directed chemotherapy for acute myeloid leukemia (AML) may permit more treatment to be administered without escalating toxicity. Gemtuzumab ozogamicin (GO) is an immunoconjugate between CD33 and calicheamicin that internalized when binding the epitope. We previously established it feasible combine GO with conventional chemotherapy. now report a large randomized trial testing addition of induction and/or consolidation in untreated younger patients. Patients Methods In this...
Abstract BACKGROUND The survival of older patients with acute myeloid leukemia has not improved. Few clinical trials have been available for who are considered fit an intensive chemotherapy approach. METHODS Between December 1998 and November 2003, as part National Cancer Research Institute Acute Myeloid Leukemia 14 Trial, 217 patients, were deemed unfit randomized to receive low‐dose cytarabine (Ara‐C) (20 mg twice daily 10 days) or hydroxyurea without all‐trans retinoic acid (ATRA)....
Purpose Risk stratification in acute myeloid leukemia (AML) is currently based on pretreatment characteristics. It remains to be established whether relapse risk can better predicted through assessment of minimal residual disease (MRD). One proposed marker the Wilms tumor gene WT1, which overexpressed most patients with AML, thus providing a putative target for immunotherapy, although absence standardized assay, its utility MRD monitoring controversial. Patients and Methods Nine published...
There has been little survival improvement in older patients with acute myeloid leukemia (AML) the last two decades. Improving induction treatment may improve rate and quality of remission consequently survival. In our previous trial, younger patients, we showed improved for majority when adding gemtuzumab ozogamicin (GO) to chemotherapy.Untreated AML or high-risk myelodysplastic syndrome (median age, 67 years; range, 51 84 years) were randomly assigned receive chemotherapy either...
Treatment outcomes in younger patients with acute myeloid leukemia (AML) have improved, but optimization and new combinations are needed. We assess three induction consolidation.Younger untreated AML (median age, 49 years; range, 0 to 73 years) were randomly allocated two courses of daunorubicin cytarabine (DA) or without etoposide (ADE; n = 1983) ADE versus fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin (FLAG-Ida; 1268), amsacrine, etoposide, then...
Molecular diagnostics and early assessment of treatment response that use methodologies capable detecting submicroscopic disease can distinguish subgroups patients with leukemia at differing relapse risk. Such information is being incorporated into risk-stratified protocols; however, there are few data concerning prospective sequential minimal residual (MRD) monitoring to identify more precisely those destined experience relapse, which would allow tailored therapies.Real-time quantitative...
Older patients with acute myeloid leukemia (AML) have a high relapse rate after standard chemotherapy. We investigated whether measuring chemotherapy sensitivity by multiparameter flow cytometric minimal residual disease (MFC-MRD) detection has prognostic value in older than age 60 years or is simply surrogate for known age-related risk factors.Eight hundred ninety-two unselected treated intensively the United Kingdom National Cancer Research Institute AML16 Trial were assessed prospectively...
Karyotype is an independent indicator of prognosis in acute myeloid leukemia (AML) that widely applied to risk-adapted therapy. Because AML rare children, the true prognostic significance individual chromosomal abnormalities this age group remains unclear.This cytogenetic study 729 childhood patients classified them into 22 subgroups and evaluated their incidence risk.Rearrangements 11q23 were most frequent abnormality found approximately 16% patients, with 50% these infants. The outcome for...
Purpose To determine the clinical relevance of mutations in CCAAT/enhancer binding protein α (CEBPA) gene acute myeloid leukemia (AML) and to examine factors that might modify prognostic impact. Patients Methods The entire CEBPA coding sequence was screened 1,427 young adult patients with AML, excluding promyelocytic leukemia, using denaturing high-performance liquid chromatography direct sequencing. Results Of 107 (7%) mutations, 48 (45%) had one mutation (CEBPA-single), 59 (55%) two...